WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

4 6477 2040 7 4 2	tional Patent Classification 7:		(11) International Publication Number:	WO 00/14236
C12N 15/16, C07K 14/60, A61K 38/25, G01N 33/68 A2 (43) International Publication Date:	13/10, CO/11 14/00, 110111 20/22,	A2	(43) International Publication Date:	16 March 2000 (16.03.00)

PCT/CA99/00816 (21) International Application Number:

7 September 1999 (07.09.99) (22) International Filing Date:

(30) Priority Data: 09/148,982 8 September 1998 (08.09.98)

US US 3 September 1999 (03.09.99) 09/389,486

(71) Applicant (for all designated States except US): THERATE-CHNOLOGIES INC. [CA/CA]; 5ème Etage, 630 Boulevard René-Lévesque Ouest, Montréal, Québec H3B 1S6 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRAVEL, Denis [CA/CA]; 207 Des Pyrénées, St-Lambert, Québec J4S 1L3 (CA). HABI, Abdelkrim [CA/CA]; 7961 Champ d'Eau, Anjou, Québec H1J 1X4 (CA). BRAZEAU, Paul [CA/CA]; 4054 Avenue du Parc Lafontaine, Montréal, Québec H2L 3M8 (CA).

(74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY

(57) Abstract

The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include a hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

Ę Į.